Prenatal Screening Tests Devices Market Research Report: Information By Test (Alpha-Fetoprotein (AFP) Tests, Free Beta Human Chorionic Gonadotropin (hCG) Tests, Inhibin A Tests, Non-invasive prenatal testing (NIPT), Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, and Unconjugated Estriol (uE3) Tests), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Prenatal screening tests devices Market Overview

Prenatal screening tests devices Market Size was valued at USD 0.72 Billion in 2022. The prenatal screening tests devices industry is projected to grow from USD 0.80 Billion in 2023 to USD 2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.00% during the forecast period (2023 - 2032). An increased understanding of the value of prenatal screening for the early identification of fetal abnormalities among pregnant parents and healthcare professionals are the key market drivers boosting the expansion of the market.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Prenatal screening tests devices Market Trends

• Growing maternal age is driving the market growth

Market CAGR for prenatal screening tests devices is being driven by the Growing Maternal Age. Prenatal testing gives you details about the health of your unborn child. It finds any issues, including as genetic flaws and congenital disorders that might have an impact on the health of fetuses. While some women require specialized screening procedures, doctors advise certain prenatal screenings. Testing is done on newborns to find anomalies that may lead to inborn genetic disorders or other health issues. During screening, genetic disorders such as homocystinuria, phenylketonuria, and Down syndrome can be identified in neonates.

Additionally, the tendency to put off having children raises the risk of chromosomal abnormalities and genetic illnesses in babies. Prenatal screening tests to identify such anomalies are becoming more and more necessary as more women want to become pregnant at older ages. Growth in the industry is stimulated by increased healthcare spending, particularly in developed and emerging nations where it leads to better access to screening tests and prenatal care. However, due to high costs or inadequate healthcare infrastructure, access to advanced prenatal screening tests may be restricted in some areas or healthcare settings, which could have an impact on broad adoption.

A greater frequency of chromosomal abnormalities and genetic illnesses in babies is a result of the trend of postponing delivery. Prenatal screening tests are becoming more and more necessary to identify these anomalies as more women choose to become pregnant at older ages. Prenatal screening tests that don't involve risk are more frequently adopted because expectant parents are drawn to non-invasive, risk-free ways of keeping an eye on their unborn child's health. Prenatal screening tests are in high demand because early discovery of fetal anomalies enables better medical management and educates parents and healthcare providers in making decisions. For instance, the World Health Organization (WHO) estimates that congenital anomalies account for 6% of all births ly and are a major contributor to the  illness burden, particularly in low- and middle-income nations. Additionally, the Prenatal and Newborn Genetic Testing Market Size is positively impacted by the increase in demand for non-invasive prenatal screening. Thus, result in driving the prenatal screening tests devices market revenue.

Prenatal screening tests devices Market Segment Insights

Prenatal screening tests devices Test Insights

The  prenatal screening tests devices market segmentation, based on test includes Alpha-Fetoprotein (AFP) Tests, Free Beta Human Chorionic Gonadotropin (hCG) Tests, Inhibin A Tests, Non-invasive prenatal testing (NIPT), Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, and Unconjugated Estriol (uE3) Tests. The non-invasive prenatal testing (NIPT) segment dominated the market. A blood test called NIPT is more precise than the initial pregnancy screening exam. It is provided to expectant mothers whose unborn child has been diagnosed with a higher probability of developing Down syndrome, Edwards’s syndrome, or Patau syndrome based on results from prior screening tests.

Figure1:  Prenatal screening tests devices Market, by Test, 2022&2032(USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Prenatal screening tests devices Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American prenatal screening tests devices market area will dominate this market. Newborns in North America are more likely to have chromosomal abnormalities and genetic illnesses as a result of the tendency of women delaying childbirth. As a result, older pregnant mothers are calling for prenatal screening tests more frequently.

Further, the major countries studied in the market report are The US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

Figure2:  PRENATAL SCREENING TESTS DEVICES MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe prenatal screening tests devices market has the second-largest portion of the market. Prenatal screening test uptake and general availability are supported by this infrastructure. Further, the German prenatal screening tests devices market held the largest proportion of the market, and the UK prenatal screening tests devices market was the European market with the quickest rate of growth.

The Asia-Pacific Prenatal screening tests devices Market has the quickest predicted compound annual growth rate (CAGR) between 2023 and 2032. Infrastructure improvements for healthcare, particularly in the region's fast developing economies. Moreover, China’s prenatal screening tests devices market had the biggest market share, and the Indian prenatal screening tests devices market was the Asia-Pacific region's fastest-growing market.

Prenatal screening tests devices Key Market Players& Competitive Insights

Leading market players are putting a lot of money on R&D to expand their product lines, which will drive the market for prenatal screening test devices to continue growing. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, prenatal screening tests devices industry must provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the  prenatal screening tests devices industry to help customers and expand the market segment. In recent years, the prenatal screening tests devices industry has provided some of the biggest benefits to medicine. Major players in the prenatal screening tests devices market, including Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, Roche Diagnostics International Ltd, PerkinElmer Inc, Beckman Coulter Inc., and others, are engaging in research and development activities in an effort to boost market demand.

Illumina creates and sells integrated solutions for biological function and genetic variation analysis. Illumina recorded revenue growth of about 6% in 2019. The business put forth an acquisition proposal for Pacific Biosciences that same year for $8.00 per share, or about $1.2 billion. Illumina revealed in 2020 that it will pay $8 billion in cash and stock to purchase Grail. The goal of Illumina's iHope Genetic Health program, which was launched in 2021 in partnership with Genetic Alliance, is to give low- and middle-income populations affected by genetic disease access to whole genome sequencing.

BGI Genomics is a Chinese genomics company that offers genomic testing and research services to medical organizations, research institutes, businesses, and public agencies. The functional microbiome analyses were made possible by the publication of 1,520 reference genomes from farmed human gut bacteria by BGI Genomics in 2019. Using its in-house DNBSEQ TM technology platform, BGI has been offering a rapid whole genome sequencing (rWGS) service since 2019. This service is designed to expedite the processing of massive sequencing data. A BGI subsidiary, Forensic Genomics International, developed a nationwide genetic profile database that was compatible with WeChat in the same year.

Key Companies in the prenatal screening tests devices market include

• Illumina Inc


• BGI Genomics Co Ltd


• Yourgene Health Plc


• Eurofins Scientific SE


• Agilent Technologies Inc


• Roche Diagnostics International Ltd


• PerkinElmer Inc


• Beckman Coulter Inc


• Abbott Laboratories


• Siemens Healthineers AG


• Quidel Corp


• Thermo Fisher Scientific Inc


• Tosoh Corp

Prenatal screening tests devices Industry Developments

October 2022:Eurofins commissioned a study that revealed the company has delivered a total shareholder return of about 36,600% since its IPO.

August 2020:Agilent announced the expansion of its cutting-edge production facility in Frederick, Colorado, which is responsible for the development and production of "oligos," which are small molecules of DNA and RNA that are utilized to produce therapies based on nucleic acids.

January 2023:Agilent revealed plans to expand its life science plant in Frederick, Colorado, for $725 million. With this move, the company will be able to increase its manufacturing capacity at the property located outside of Denver.

Prenatal screening tests devices Market Segmentation

Prenatal screening tests devices Test Outlook

• Alpha-Fetoprotein (AFP) Tests


• Free Beta Human Chorionic Gonadotropin (hCG) Tests


• Inhibin A Tests


• Non-invasive prenatal testing (NIPT)


• Pregnancy Associated Plasma Protein A (PAPP-A) Tests


• Total Human Chorionic Gonadotropin (hCG) Tests


• Unconjugated Estriol (uE3) Tests

Prenatal screening tests devices Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America